Custom Slice Xpanded® (greater than 150 genes)
Use
The Custom Slice Xpanded® test leverages whole-exome capture and sequencing; however, analysis and reporting are restricted to a provider-specified gene list exceeding 150 genes. This phenotype-driven targeted exome approach is well suited for individuals with complex or heterogeneous clinical presentations for which no standard panel exists. Results are focused on the custom gene set and do not include ACMG secondary findings unless those genes are on the submitted list.
Special Instructions
Providers must submit a custom gene list via the Slice Tool portal. Upon approval (within approximately three business days), GeneDx will provide a tracking number and coverage metrics that must accompany the sample. Depending on availability and family structure, proband-only or trio (including biological parents) samples may be used; inclusion of other relatives requires prior approval.
Limitations
Analysis is confined strictly to the provider-submitted gene list; secondary findings from comprehensive exome sequencing are not reported unless included in that list. The analytic and reporting process is phenotype driven and may not include all detected variants. Family member inclusion must adhere to policy timelines and approval processes.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided